The pentose phosphate pathway (PPP) is a cytosolic metabolic route that runs parallel to glycolysis, branching from Glucose-6-phosphate to generate two products of profound biological importance: NADPH (the cell's primary reducing currency) and ribose-5-phosphate (the sugar backbone of nucleotides and nucleic acids). Unlike glycolysis, which is primarily an energy-yielding pathway producing ATP, the PPP is fundamentally a biosynthetic and protective pathway -- it supplies the reducing equivalents that maintain antioxidant defense, drive fatty acid synthesis and cholesterol biosynthesis, and power the Reactive Oxygen Species-generating NADPH oxidase system in phagocytes.
In cPNI, the pentose phosphate pathway occupies a uniquely important position because it sits at the intersection of Immunometabolism and Oxidative Stress defense. Activated neutrophils and macrophages dramatically upregulate PPP flux to fuel the respiratory burst that kills pathogens -- yet the same NADPH is simultaneously needed to regenerate glutathione and protect the host's own tissues from oxidative damage. This dual role makes the PPP a metabolic fulcrum: when the pathway is impaired (as in G6PD deficiency), both antimicrobial capacity and antioxidant resilience suffer, creating a vulnerability that affects over 400 million people worldwide.
The PPP also connects deeply to the nutritional and evolutionary themes central to cPNI. The rate-limiting enzyme G6PD is under selective pressure from malaria (G6PD deficiency confers protection against Plasmodium falciparum), while the non-oxidative phase depends entirely on Transketolase, a thiamine (Vitamin B1)-dependent enzyme whose failure in deficiency states produces Wernicke's encephalopathy. These connections illustrate how a single metabolic pathway links infectious disease, nutritional status, neurological function, and immune competence.
The oxidative phase is the committed, NADPH-generating arm of the PPP and consists of three sequential reactions. First, G6PD -- the rate-limiting enzyme of the entire pathway -- oxidizes Glucose-6-phosphate to 6-phosphogluconolactone, reducing NADP+ to NADPH in the process. This is the most tightly regulated step and the point at which pathway flux is controlled. The NADP+/NADPH ratio is the primary regulator: when NADPH is consumed (by glutathione reductase activity during Oxidative Stress, or by NADPH oxidase during respiratory burst), the rising NADP+ concentration activates G6PD and drives flux through the pathway. G6PD expression is also transcriptionally induced by Nrf2 under oxidative stress conditions and by HIF-1 under hypoxia.
Second, 6-phosphogluconolactonase hydrolyzes the lactone to 6-phosphogluconate. Third, 6-phosphogluconate dehydrogenase performs a second oxidative decarboxylation, producing ribulose-5-phosphate, CO2, and a second molecule of NADPH. Thus, for every molecule of Glucose-6-phosphate traversing the oxidative phase, two molecules of NADPH are generated. This NADPH cannot be used directly by the electron transport chain for ATP synthesis; instead, it serves as the dedicated reducing agent for biosynthetic reactions and redox defense.
The non-oxidative phase is a series of reversible sugar rearrangement reactions catalyzed by Transketolase (which transfers two-carbon ketol units) and transaldolase (which transfers three-carbon dihydroxyacetone units). These enzymes interconvert C3, C4, C5, C6, and C7 sugar phosphates, effectively connecting the PPP to glycolysis by producing fructose-6-phosphate and glyceraldehyde-3-phosphate -- both glycolytic intermediates. This bidirectional connection means that when the cell needs NADPH but not ribose-5-phosphate, the non-oxidative phase can recycle the carbon skeletons back into glycolysis. Conversely, when DNA synthesis demands ribose-5-phosphate (as during rapid immune cell proliferation), glycolytic intermediates can flow in reverse through the non-oxidative phase.
Transketolase absolutely requires thiamine pyrophosphate (the active form of Vitamin B1) as a cofactor. In thiamine deficiency -- common in alcohol use disorder, malnutrition, and bariatric surgery patients -- Transketolase activity drops, impairing both the recycling of sugars and the overall efficiency of the PPP. Clinically, this manifests as Wernicke's encephalopathy (confusion, ataxia, ophthalmoplegia), because neurons are exquisitely sensitive to the combined loss of NADPH-dependent antioxidant defense and impaired nucleotide synthesis. Erythrocyte transketolase activity is used as a functional biomarker of thiamine status: a thiamine pyrophosphate effect >25% indicates deficiency.
The NADPH generated by the PPP serves several essential functions that are directly relevant to cPNI:
Antioxidant defense via glutathione: glutathione reductase uses NADPH to convert oxidized glutathione (GSSG) back to reduced glutathione (GSH), maintaining the GSH/GSSG ratio that is the cell's primary redox buffer. Red blood cells, which lack Mitochondria and depend entirely on the PPP for NADPH, are especially vulnerable when this system fails -- hence the hemolytic anemia of G6PD deficiency.
Respiratory burst in phagocytes: NADPH oxidase (NOX2) in neutrophils and macrophages consumes massive quantities of NADPH to generate superoxide (O2-), which is then converted to hypochlorous acid, hydrogen peroxide, and other microbicidal Reactive Oxygen Species. During phagocytosis, PPP activity in neutrophils increases 10- to 20-fold. This explains why G6PD-deficient individuals suffer increased susceptibility to bacterial and fungal infections -- their phagocytes cannot mount an adequate respiratory burst.
Biosynthesis: NADPH provides the reducing equivalents for de novo fatty acid synthesis (via fatty acid synthase), cholesterol synthesis (via HMG-CoA reductase), and steroid hormone synthesis. It is also required for the production of Nitric Oxide by nitric oxide synthase (NOS) and for cytochrome P450 reactions in drug and toxin metabolism.
Ribose-5-phosphate for nucleotide synthesis: Rapidly proliferating cells -- including activated lymphocytes, wound-healing fibroblasts, and tumor cells -- require ribose-5-phosphate for DNA and RNA synthesis. This is why Cancer cells frequently upregulate G6PD and the PPP (complementing the Warburg Effect), and why activated immune cells increase PPP flux during clonal expansion.
G6PD deficiency is the most common enzymopathy in the world, affecting approximately 400 million people with an X-linked inheritance pattern that predominantly affects males. The condition exemplifies evolutionary medicine principles: the same mutations that impair NADPH production in red blood cells also impair the ability of Plasmodium falciparum to parasitize those cells, conferring up to 50% protection against severe malaria. The geographic distribution of G6PD deficiency mirrors historical malaria prevalence -- a textbook example of balancing selection.
Clinically, G6PD-deficient individuals are vulnerable to hemolytic crises triggered by Oxidative Stress: infections (the most common trigger), certain drugs (primaquine, sulfonamides, dapsone), fava beans (favism), and high-dose vitamin C. The hemolysis occurs because red blood cells cannot regenerate glutathione without adequate NADPH, leaving hemoglobin and membrane lipids unprotected from oxidative damage. Heinz bodies (denatured hemoglobin aggregates) form, and the damaged cells are cleared by splenic macrophages.
In cPNI practice, G6PD status must be considered before prescribing pro-oxidant interventions, high-dose vitamin C, or certain antimicrobial protocols. G6PD-deficient patients also have impaired neutrophil respiratory burst, increasing susceptibility to catalase-positive organisms (Staphylococcus, Aspergillus, Serratia) -- a pattern resembling chronic granulomatous disease.
The PPP is central to Immunometabolism. Upon activation, macrophages undergoing M1 polarization dramatically increase PPP flux alongside Aerobic Glycolysis (the immune Warburg Effect). This metabolic reprogramming serves dual purposes: providing NADPH for the respiratory burst and for Nitric Oxide production via iNOS, and generating ribose-5-phosphate for the nucleotide synthesis needed for cytokine mRNA production and cell proliferation. The citric acid cycle is simultaneously broken at two points (after citrate and after succinate), redirecting metabolites toward inflammatory mediator synthesis.
Neutrophils, as short-lived cells that rely almost entirely on glycolysis and the PPP (having few Mitochondria), are especially dependent on this pathway. The respiratory burst consumes so much NADPH that neutrophils can exhaust their PPP capacity within minutes of activation -- which partly explains why neutrophil killing is intense but brief.
Because Transketolase requires thiamine pyrophosphate, Vitamin B1 deficiency impairs the non-oxidative phase of the PPP, reducing NADPH regeneration capacity and nucleotide synthesis. The brain is disproportionately affected because neurons have high metabolic demands, limited antioxidant reserves, and depend on nucleotide turnover for neurotransmitter synthesis and synaptic function. Wernicke's encephalopathy -- acute confusion, ataxia, and eye movement abnormalities -- results from thiamine-depleted neurons in the mammillary bodies, thalamus, and periaqueductal gray matter. This condition is a medical emergency requiring immediate parenteral thiamine (before Glucose administration, as Glucose loading further depletes thiamine by driving glycolysis and the PPP).
Cancer cells upregulate G6PD and the PPP to support both rapid proliferation (ribose-5-phosphate for DNA replication) and survival under Oxidative Stress (NADPH for glutathione and thioredoxin systems). Oncogenic signaling through AKT, mTOR, and NF-κB pathways directly stimulates PPP enzyme expression. This makes PPP enzymes potential therapeutic targets, and G6PD inhibitors are under investigation as anti-cancer agents.